The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Gene expression profile signature (DecisionDx-Melanoma) to predict visceral metastatic risk in patients with stage I and stage II cutaneous melanoma.
Navneet Dhillon
Research Funding - Castle Biosciences
Anna R Rogers
No relevant relationships to disclose
Keith A. Delman
No relevant relationships to disclose
Derek Maetzold
Employment or Leadership Position - Castle Biosciences
Stock Ownership - Castle Biosciences
Kristen M. Oelschlager
Employment or Leadership Position - Castle Biosciences
Stock Ownership - Castle Biosciences
Stephen Lyle
No relevant relationships to disclose
Gilchrist L. Jackson
No relevant relationships to disclose
Anthony Greisinger
No relevant relationships to disclose
Douglas Parker
No relevant relationships to disclose
Robert W. Cook
Employment or Leadership Position - Castle Biosciences
Stock Ownership - Castle Biosciences
Research Funding - Castle Biosciences
David H. Lawson
No relevant relationships to disclose